Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment
Launch Of Humira Challenger In 2023 May Rejuvenate The Area
Executive Summary
Pfizer appears to be maintaining its “opportunistic” approach to biosimilars, having ceased to split out the business unit’s results during its Q3 earnings report.
You may also be interested in...
Prestige Takes Trastuzumab A Step Closer To US Filing
Prestige says a meeting with the FDA in November represents a “final step” before filing its trastuzumab biosimilar with the US agency by the end of the year. Meanwhile, a major shareholder has invested further in the Singapore-based biosimilars developer.
Amneal Makes First Biosimilar Launch With US Bevacizumab
Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.
Prestige Pulls Trastuzumab After EMA Knockback
Prestige Biopharma has formally withdrawn its marketing authorization application for its Tuznue (trastuzumab) biosimilar candidate, following a negative opinion from the EMA’s CHMP as well as a requested re-examination.